Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma
Public ClinicalTrials.gov record NCT02667886. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to test different doses of X4P-001 given alone and in combination with axitinib in participants diagnosed with advanced renal cell carcinoma. The goals of the study are to determine the safety and tolerability of X4P-001, as well as the potential effect it may have on the body and the cancer tumor.
Study identification
- NCT ID
- NCT02667886
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 74 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 27, 2016 (Actual)
- Primary completion
- Apr 14, 2022 (Actual)
- Completion
- Apr 14, 2022 (Actual)
- Last update posted
- Oct 3, 2024
2016 – 2022
United States locations
- U.S. sites
- 18
- U.S. states
- 17
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Scottsdale | Arizona | 85259 | — |
| Not listed | Washington D.C. | District of Columbia | 20057 | — |
| Not listed | Jacksonville | Florida | 32224 | — |
| Not listed | Chicago | Illinois | 60637 | — |
| Not listed | Indianapolis | Indiana | 46237 | — |
| Not listed | Iowa City | Iowa | 52242 | — |
| Not listed | New Orleans | Louisiana | 70121 | — |
| Not listed | Boston | Massachusetts | 02215 | — |
| Not listed | Detroit | Michigan | 48201 | — |
| Not listed | Saint Paul | Minnesota | 55101 | — |
| Not listed | St Louis | Missouri | 63110 | — |
| Not listed | Hackensack | New Jersey | 07601 | — |
| Not listed | New York | New York | 10029 | — |
| Not listed | The Bronx | New York | 10461 | — |
| Not listed | Toledo | Ohio | 43623 | — |
| Not listed | Philadelphia | Pennsylvania | 19104 | — |
| Not listed | Greenville | South Carolina | 29605 | — |
| Not listed | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02667886, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 3, 2024 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02667886 live on ClinicalTrials.gov.